Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05524571 · ClinicalTrials.gov registry record · Phase 3
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
A Phase 3 study of Thyroid Eye Disease, sponsored by Immunovant Sciences.
- Active
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT05524571 is a Phase 3 study of Thyroid Eye Disease that is active but no longer recruiting, run by Immunovant Sciences. The registered enrollment target is 100 participants, roughly in line with the 100-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target. The trial reports 20 study locations across 12 states.
The verdict
NCT05524571, a Phase 3 study of Thyroid Eye Disease, is active but no longer recruiting, sponsored by Immunovant Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Batoclimab
Study Locations (20)
Other
- Site Number - 7565 - Sydney
- Site Number -4671 - Bruges
- Site Number - 4672 - Brussels
- Site Number - 4673 - Brussels
- Site Number -4670 - Ghent
California
- Site Number -1520 - Pasadena
- Site Number -1517 - San Francisco
- Site Number -1514 - Torrance
Texas
- Site Number -1515 - Bellaire
- Site Number - 1524 - McAllen
- Site Number -1519 - San Antonio
Florida
- Site Number -1510 - Sarasota
Kentucky
- Site Number -1516 - Louisville
Michigan
- Site Number - 1526 - Livonia
Minnesota
- Site Number - 1513 - Rochester
North Carolina
- Site Number - 1512 - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-01-05 |
| Est. Completion | 2026-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05524571
The ClinicalTrials.gov registry entry for NCT05524571 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 100-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target. The listed sponsor is Immunovant Sciences, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05524571 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Texas.
Frequently Asked Questions
What is clinical trial NCT05524571 about?
NCT05524571 is a clinical study titled "Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease". To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
What is the current status of trial NCT05524571?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2023-01-05. Estimated completion is 2026-03.
What conditions does trial NCT05524571 study?
This clinical trial studies the following conditions: Thyroid Eye Disease.
What interventions are being tested in trial NCT05524571?
The interventions under investigation include: Placebo (DRUG), Batoclimab (DRUG).
Who is sponsoring clinical trial NCT05524571?
This trial is sponsored by Immunovant Sciences, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05524571 being conducted?
This trial has 20 study locations across California, Florida, Kentucky, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.